{
    "nct_id": "NCT03748134",
    "official_title": "A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)",
    "inclusion_criteria": "* Histopathologically confirmed unresectable, locally advanced, recurrent or metastatic ESCC (excluding mixed adenosquamous carcinoma and other histological subtypes)\n* ECOG PS of 0 or 1\n* Subject must be unsuitable for definitive treatment, such as definitive chemoradiotherapy and/or surgery. For subjects who have received (neo)adjuvant or definitive chemotherapy/radiochemotherapy, time from the completion of last treatment to disease recurrence must be > 6 months Could provide archival or fresh tissues for PD-L1 expression analysis with obtainable results\n* Have at least one measurable lesion as per RECIST v1.1\n\nKey exclusion Criteria:\n\n* ESCC with endoscopy-confirmed near-complete obstruction requiring interventional therapy\n* Post stent implantation in the esophagus or trachea with risk of perforation\n* Received systemic treatment for advanced or metastatic ESCC.\n* Received a cumulative dose of cisplatin â‰¥ 300 mg/m2 and the last cisplatin dose was within 12 months of randomization or the first dose of study treatment in the open-label phase.\n* High risk of hemorrhage or perforations due to tumor invasion in adjacent organs (aorta or trachea), or have fistula formation.\n* Hepatic metastasis > 50% of the total liver volume.\n* Received palliative therapy for a local lesion within 2 weeks prior to the first dose.\n* Received systemic treatment with Chinese traditional medicines with anti-cancer indications or immunomodulators (including thymosins, interferons, and interleukins) within 2 weeks prior to the first dose of study treatment.\n* Received systemic immunosuppressants within 2 weeks prior to randomization, excluding local use of glucocorticoids administered by nasal, inhaled, or other routes, and systemic glucocorticoids at physiological doses (no more than 10 mg/day of prednisone or equivalents), or glucocorticoids to prevent allergies to contrast media.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": "Key"
}